641 related articles for article (PubMed ID: 26027790)
41. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
O'Meara MM; Simon JA
Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
[TBL] [Abstract][Full Text] [Related]
42. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
43. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
44. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
45. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
46. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
Van Aller GS; Pappalardi MB; Ott HM; Diaz E; Brandt M; Schwartz BJ; Miller WH; Dhanak D; McCabe MT; Verma SK; Creasy CL; Tummino PJ; Kruger RG
ACS Chem Biol; 2014 Mar; 9(3):622-9. PubMed ID: 24304166
[TBL] [Abstract][Full Text] [Related]
47. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
48. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
[TBL] [Abstract][Full Text] [Related]
49. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
50. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
51. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.
Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC
Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960
[TBL] [Abstract][Full Text] [Related]
52. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
[TBL] [Abstract][Full Text] [Related]
53. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
[TBL] [Abstract][Full Text] [Related]
54. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
[TBL] [Abstract][Full Text] [Related]
55. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
56. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
57. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
Verma SK
Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
[TBL] [Abstract][Full Text] [Related]
59. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
60. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
